CN1122529C - Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation - Google Patents
Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation Download PDFInfo
- Publication number
- CN1122529C CN1122529C CN 01114118 CN01114118A CN1122529C CN 1122529 C CN1122529 C CN 1122529C CN 01114118 CN01114118 CN 01114118 CN 01114118 A CN01114118 A CN 01114118A CN 1122529 C CN1122529 C CN 1122529C
- Authority
- CN
- China
- Prior art keywords
- biological food
- therapeutic health
- food therapeutic
- diabetes
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a biologic dietary health-care product containing MT and a preparation method thereof, which is suitable for diabetes and complicating diseases thereof. The biologic dietary health-care product mainly utilizing that the MT has the functions of protecting and repairing diabetic patients' genes and islet beta cells and enhancing the sensitivity of acceptors of insulin target cells has the function of regulating blood sugar and has effect on complicating diseases. The biologic dietary health-care product comprises the principal components: MT, barbary wolfberry fruit, glutamine, beta-cyclodextrin and glucoprotein. An oral liquid is prepared by uniform mixing, filtration, separate loading, sterilization, lamp examination, packaging, etc.
Description
The present invention relates to a kind of containing metal sulfoprotein (Metallothionein is hereinafter to be referred as MT) biological food therapeutic health that is applicable to diabetes and intercurrent disease treatment thereof.
The invention still further relates to the manufacture method of this biological food therapeutic health.
Diabetes are the clinical syndromes that interacted and caused by gene and environmental factors.Because of hypoinsulinism and target tissue cell reduce insulin sensitivity, cause a series of metabolism disorders such as sugar, albumen, fat, power and water Xie Zhi.Clinical is main common sign with the hyperglycemia, and prolonged illness can cause a plurality of system damages.Show as " three-many-one-little ", i.e. polydipsia, polyphagia, polyuria and lose weight.Suffer from the concurrent hypertension of long meeting of diabetes time, arteriosclerosis, cardiovascular disease, kidney disease, cataract etc.It is reported that the diabetics of China is about 70,000,000 crowd.Diabetes and intercurrent disease thereof still do not have specific medicament and specific short up to now, and the symptomatic treatment drug side effect is more at present, often causes liver, injury of kidney.Human life's health in diabetes and intercurrent disease serious threat thereof, is a global medical science health problem.
An aspects cosmopolitan medicine difficult problem above the inventor just solves has finished being applicable to diabetes and intercurrent disease biological food therapeutic health oral liquid and technology thereof treatment, that contain MT.The biological food therapeutic health oral liquid that contains MT and the technology thereof that are applicable to the treatment of diabetes and intercurrent disease have become urgent need.
Task of the present invention realizes as follows:
The prescription that contains the MT biological food therapeutic health that is used for diabetes and intercurrent disease: prescription: every 15ml of loading amount
MT (Meta llothionein metallothionein) 6.5mg/100ml
Fructus Lycii 10000mg/100ml
Glutamine (L-Glrlamin) 0.67mg/100ml
Cycloheptaamylose 200mg/100ml
Protein sugar 250mg/100ml technology:
MT → MT liquid → spray bottle sterilization ← wash bottle
↓ ↓ Fructus Lycii → clean → extract → concentrate → filtration → ingredients → fill → sterilization → → lamp inspection → packing → finished product ↑
Glutamine, cycloheptaamylose, protein sugar
The present invention's process is used a large amount of observations of the physiological function pharmacological action of MT, identify MT and have significant removing OH-free radical, repair gene, the activation beta Cell of islet, the activation biomembrane, the effect of minimizing insulin resistant, and on this basis, through prescription, making, invented the biological food therapeutic health that contains MT.
The active ingredient of the biological food therapeutic health oral liquid of the MT of containing of the present invention is MT, is meant a class low-molecular-weight, high sulfhydryl content, can be in a large number in conjunction with the protein or the active polypeptide of the unique properties of heavy metal ion.All MT have 61 amino acid residues in the mammal, and each molecule has the monovalent metallic ion of 7 bivalent metal ions or 10 atoms to combine, and MT does not contain aromatic series or histidine residues.20 cysteine residues are arranged in the amino acid residue of mammals MT.Confirm that after deliberation MT has protection and repair to diabetes patient's gene, has repair to the beta Cell of islet that damages.Simultaneously find that also MT can increase the sensitivity of Insulin receptor INSR, promote the conciliation blood glucose effect of self insulin.Other composition has the effect of stabilizing and increasing the MT effect in the prescription.Big quantity research and application show that the MT oral liquid is applicable to diabetes and intercurrent disease thereof: the people of hypertension, coronary heart disease, arteriosclerosis, lower limbs necrosis, cataract disease has special efficacy.
Purpose of the present invention: what be applicable to diabetes and intercurrent disease thereof contains the MT biological food therapeutic health.The pharmacological action of the MT of containing biological food therapeutic health of the present invention is to remove separating of free radical pathological gene; repair and protecting group because of; the activation beta Cell of islet; recover and the increase cell function; the activation biomembrane improves the sensitivity that strengthens Insulin receptor INSR, the enhancing immunity blood sugar regulation; blood sugar lowering, effective to intercurrent disease simultaneously.The MT oral liquid has: 1, gene 3, enhancing immunity 4, antioxidation, slow down aging 5, biologic detoxication are repaired in blood sugar regulation 2, protection, separate lead, hydrargyrum poison 6, antitumor, radioprotective 7, resisting fatigue.
Claims (2)
1, a kind of containing metal sulfoprotein biological food therapeutic health that is applicable to diabetes and intercurrent disease thereof is characterized in that: contain in the prescription
Metallothionein 6.5mg/100ml
Fructus Lycii 10000mg/100ml
Glutamine 0.67mg/100ml
Cycloheptaamylose 200mg/100ml
Protein sugar 250mg/100ml.
2, a kind of method that is used to make the described containing metal sulfoprotein of claim 1 biological food therapeutic health, it is characterized in that: at first Fructus Lycii is extracted, concentrates, filters the back and add metallothionein, glutamine, cycloheptaamylose, protein sugar, the back fill stirs.Be the finished product oral liquid through sterilization, lamp inspection, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114118 CN1122529C (en) | 2001-06-19 | 2001-06-19 | Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01114118 CN1122529C (en) | 2001-06-19 | 2001-06-19 | Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1391953A CN1391953A (en) | 2003-01-22 |
| CN1122529C true CN1122529C (en) | 2003-10-01 |
Family
ID=4660793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01114118 Expired - Fee Related CN1122529C (en) | 2001-06-19 | 2001-06-19 | Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1122529C (en) |
-
2001
- 2001-06-19 CN CN 01114118 patent/CN1122529C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1391953A (en) | 2003-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4353982B2 (en) | Synergistic composition for the treatment of diabetes | |
| KR100750988B1 (en) | Composition having ginsenosides for treating or preventing diabetes | |
| Agrawal et al. | Effect of oyster mushroom on glycemia, lipid profile and quality of life in type 2 diabetic patients | |
| CN110420315A (en) | Application of the Lycium chinense glycopeptide in preparation three high drugs for the treatment of | |
| CN108420065A (en) | A kind of antihypelipidemic product rich in bitter gourd polypeptide | |
| Ravichandran | Studies on gymnemic acids nanoparticulate formulations against diabetes mellitus | |
| US11044930B2 (en) | Composition comprising cinnamon extract | |
| CN1281225C (en) | Health-care food for diabetes mellitus patient | |
| CN105169372A (en) | Functional food for increasing bone density and improving osteoporosis and preparation method of functional food | |
| CN1122529C (en) | Biological food therapeutic health article containing metallothionein for treating diabetes and complication and its preparation | |
| US20150224161A1 (en) | Methods and uses of an extract from olive leaf in management of type 2 diabetes | |
| CN103815397B (en) | Downgrade food compositions of blood pressure, blood fat and blood sugar and preparation method thereof | |
| KR100542809B1 (en) | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus | |
| CN1262284C (en) | Health care product of hippophae rhamnoides oil | |
| Sanjari et al. | The safety and efficacy of Rosa damascena extract in patients with type II diabetes: Preliminary report of a triple blind randomized acarbose controlled clinical trial | |
| Opreh et al. | Distribution of Diabetes co-morbidities and treatment outcome of hypertension at a tertiary lifestyle medical centre in Ile-Ife, Osun State, Nigeria: A 5–Year Retrospective Study | |
| Dewi et al. | The Effectiveness Of Red Ginger Extract (Zingiber Officinale Var. Rubrum) On Decreased Blood Glucose Levels In Mice (Mus Musculus) | |
| CN111298052A (en) | Medicine for treating diabetes | |
| CN105031248A (en) | Health care product which contains Se-enriched cordyceps and is capable of assisting in blood sugar level regulation | |
| CN1895504A (en) | Chinese medicine for treating osteoporosis and its preparation | |
| CN1575803A (en) | Application method of Aloe vera L. extract in preventing and curing diabetes | |
| Aritajat et al. | Effects of selected herbal extracts on blood chemistry profiles in rats | |
| RU2201179C2 (en) | Method for treating diabetic retinopathies | |
| CN1171594C (en) | Composition containing pearl powder and ascorbic acid | |
| Moradi et al. | The effect of Carum carvil oil on the level of heat shock proteins 70 and 72 in the liver and skeletal muscle tissues in diabetic rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Guojie Document name: Correction notice |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Guojie Document name: Qualified notice of first instance |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhou Guojie Document name: payment instructions |
|
| DD01 | Delivery of document by public notice |
Addressee: Pu Jianxin Document name: Notification of Termination of Patent Right |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031001 Termination date: 20090720 |